特应性湿疹与癌症风险的关联:英格兰与丹麦的匹配队列研究
两项大型匹配队列研究分别纳入英格兰和丹麦人群,比较特应性湿疹患者与无湿疹者的癌症风险。结果显示湿疹与总体癌症及多数特定癌症无显著关联,但非皮肤淋巴瘤风险升高且随湿疹严重度增加。该发现提示需进一步研究新型免疫调节系统治疗对癌症风险的影响。
要点
- 特应性湿疹与总体癌症风险无显著关联。
- 非皮肤淋巴瘤风险随湿疹严重度增加而升高。
- 新型免疫调节系统治疗上市前需关注癌症风险。
核心结论
- 两项大型人群研究不支持特应性湿疹与多数癌症存在关联。
- 但观察到湿疹与淋巴瘤(尤其非霍奇金淋巴瘤)相关,且关联强度随湿疹严重度增加。
研究设计与样本
- 匹配队列研究,英格兰数据来自1998年1月2日至2016年3月31日,丹麦数据来自1982年1月1日至2016年6月30日。
主要发现
- 英格兰总体癌症校正HR为1.04(99%CI 1.02-1.06),丹麦为1.05(99%CI 0.95-1.16)。
- 英格兰非霍奇金淋巴瘤校正HR为1.19(99%CI 1.07-1.34),霍奇金淋巴瘤为1.48(99%CI 1.07-2.04)。
- 英格兰非霍奇金淋巴瘤风险随湿疹严重度增加:轻度HR 1.06(99%CI 0.90-1.25),中度1.24(99%CI 1.04-1.48),重度2.08(99%CI 1.42-3.04)。
- 丹麦中重度湿疹与非霍奇金淋巴瘤最低校正HR为1.31(99%CI 0.76-2.26),霍奇金淋巴瘤为1.35(99%CI 0.65-2.82),但99%CI较宽。
临床怎么用
- 临床应知晓特应性湿疹患者总体癌症风险未见明显增加。
- 对中重度湿疹患者需关注淋巴瘤风险,尤其非霍奇金淋巴瘤。
- 使用新型免疫调节系统治疗前应评估癌症风险并监测。
局限性
- 丹麦淋巴瘤分析的99%CI较宽,点估计不稳定。
- 英格兰仅纳入成人,丹麦纳入任何年龄,人群特征存在差异。
- 观察性设计无法排除残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Associations between atopic eczema and cancer are unclear, with competing theories that increased immune surveillance decreases cancer risk and that immune stimulation increases cancer risk. Establishing baseline cancer risk in people with atopic eczema is important before exploring the association between new biologic drugs for atopic eczema and cancer risk. OBJECTIVE: To investigate whether atopic eczema is associated with cancer. DESIGN, SETTING, AND PARTICIPANTS: Matched cohort studies were conducted from January 2, 1998, to March 31, 2016, in England and from January 1, 1982, to June 30, 2016, in Denmark. We conducted our analyses between July 2018 and July 2019. The setting was English primary care and nationwide Danish data. Participants with atopic eczema (adults only in England and any age in Denmark) were matched on age, sex, and calendar period (as well as primary care practice in England only) to those without atopic eczema. EXPOSURE: Atopic eczema. MAIN OUTCOMES AND MEASURES: Overall cancer risk and risk of specific cancers were compared in people with and without atopic eczema. RESULTS: In England, matched cohorts included 471 970 individuals with atopic eczema (median [IQR] age, 41.1 [24.9-60.7] years; 276 510 [58.6%] female) and 2 239 775 individuals without atopic eczema (median [IQR] age, 39.8 [25.9-58.4] years; 1 301 074 [58.1%] female). In Denmark, matched cohorts included 44 945 individuals with atopic eczema (median [IQR] age, 13.7 [1.7-21.1] years; 22 826 [50.8%] female) and 445 673 individuals without atopic eczema (median [IQR] age, 13.5 [1.7-20.8] years; 226 323 [50.8%] female). Little evidence was found of associations between atopic eczema and overall cancer (adjusted hazard ratio [HR], 1.04; 99% CI, 1.02-1.06 in England and 1.05; 99% CI, 0.95-1.16 in Denmark) or for most specific cancers. However, noncutaneous lymphoma risk was increased in people with atopic eczema in England (adjusted HR, 1.19; 99% CI, 1.07-1.34 for non-Hodgkin lymphoma [NHL] and 1.48; 99% CI, 1.07-2.04 for Hodgkin lymphoma). Lymphoma risk was increased in people with greater eczema severity vs those without atopic eczema (NHL adjusted HR, 1.06; 99% CI, 0.90-1.25 for mild eczema; 1.24; 99% CI, 1.04-1.48 for moderate eczema; and 2.08; 99% CI, 1.42-3.04 for severe eczema). Danish point estimates also showed increased lymphoma risk in people with moderate to severe eczema compared with those without atopic eczema (minimally adjusted HR, 1.31; 99% CI, 0.76-2.26 for NHL and 1.35; 99% CI, 0.65-2.82 for Hodgkin lymphoma), but the 99% CIs were wide. CONCLUSIONS AND RELEVANCE: The findings from 2 large population-based studies performed in different settings do not support associations between atopic eczema and most cancers. However, an association was observed between atopic eczema and lymphoma, particularly NHL, that increased with eczema severity. This finding warrants further study as new immunomodulatory systemic therapeutics are brought to market that may alter cancer risk.
引用
- Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association Between Atopic Eczema and Cancer in England and Denmark. JAMA Dermatol. 2020. PMID: 32579178. doi:10.1001/jamadermatol.2020.1948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。